Immunotherapy in head and neck cancer: current practice and future possibilities

被引：10
作者：
Agada, F. O. [1 ]
Alhamarneh, O. [1 ]
Stafford, N. D. [1 ]
Greenman, J. [1 ]
机构：
[1] Univ Hull, Med Res Lab, Postgrad Med Inst, Dept Otolaryngol Head & Neck Surg,Div Canc, Kingston Upon Hull HU6 7RX, N Humberside, England
来源：
JOURNAL OF LARYNGOLOGY AND OTOLOGY | 2009年 / 123卷 / 01期
关键词：
Head and Neck Neoplasms; Squamous Carcinoma; Immunotherapy; SQUAMOUS-CELL CARCINOMA; CYTOTOXIC T-LYMPHOCYTES; COMBINATION NONVIRAL INTERLEUKIN-2; TYROSINE KINASE INHIBITORS; GROWTH-FACTOR RECEPTOR; MULTICENTER PHASE-II; FACTOR-KAPPA-B; DENDRITIC CELLS; PERIPHERAL-BLOOD; MONOCYTE POLARIZATION;
D O I：
10.1017/S0022215108003356
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
The survival of patients with head and neck squamous cell carcinoma has changed little over the last 30 years. However, with recent advances in the fields of cellular and molecular immunology, there is renewed optimism with regards to the development of novel methods of early diagnosis, prognosis estimation and treatment improvement for patients with head and neck squamous cell carcinoma. Here, we present a critical review of the recent advances in tumour immunology, and of the current efforts to apply new immunotherapeutic techniques in the treatment of head and neck squamous cell carcinoma.
引用
收藏
页码：19 / 28
页数：10
相关论文
共 77 条
[1]   Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma [J].
Agarwal, A ;
Rani, M ;
Saha, GK ;
Valarmathi, TM ;
Bahadur, S ;
Mohanti, BK ;
Das, SN .
IMMUNOLOGICAL INVESTIGATIONS, 2003, 32 (1-2) :17-30
[2]  
Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO
[3]  
2-4
[4]  
Almand B, 2000, CLIN CANCER RES, V6, P1755
[5]   Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer [J].
Almand, B ;
Clark, JI ;
Nikitina, E ;
van Beynen, J ;
English, NR ;
Knight, SC ;
Carbone, DP ;
Gabrilovich, DI .
JOURNAL OF IMMUNOLOGY, 2001, 166 (01) :678-689
[6]   Exosomes as potent cell-free peptide-based vaccine.: I.: Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells [J].
André, F ;
Chaput, N ;
Schartz, NEC ;
Flament, C ;
Aubert, N ;
Bernard, J ;
Lemonnier, F ;
Raposo, G ;
Escudier, B ;
Hsu, DH ;
Tursz, T ;
Amigorena, S ;
Angevin, E ;
Zitvogel, L .
JOURNAL OF IMMUNOLOGY, 2004, 172 (04) :2126-2136
[7]  
[Anonymous], PHASE 2 CLIN TRIAL E
[8]   Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[9]  
Arteaga AL, 2003, CANCER BIOL THER, V2, pS79
[10]   Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them? [J].
Arteaga, CL ;
Baselga, J .
CANCER CELL, 2004, 5 (06) :525-531
12345678